The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MM 2018 | Emerging treatments for myeloma: quadruplets, bispecific antibodies & CAR T-cells
New therapeutic developments for multiple myeloma (MM) are showing promising results in clinical trials. Here, Heinz Ludwig, MD, PhD, from Wilhelminen Cancer Research Institute, Vienna, Austria, discusses emerging therapies for MM treatment, including quadruplet regimens, bispecifc antibodies and CAR T-cells. Speaking from the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France, Dr Ludwig highlights the need for further studies to determine the efficacy profile of bispecific antibodies in MM, as well as the need to develop an optimal strategy for CAR T-cells.
